SureNano Science Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
SureNano Science Ltd. and its subsidiary GlucaPharm Inc. are highlighted for developing GEP-44, a novel triple agonist peptide targeting the expanding GLP-1 market for obesity and metabolic disorders.
